Menarini

Over a thousand people with multiple myeloma may be eligible for treatment with Nexpovio▼ (selinexor) following NICE recommendation addressing ‘significant unmet need’ for this incurable blood cancer

NEXPOVIO has been recommended for use in the NHS, offering the opportunity to improve patient outcomes in this challenging and complex cancer NEXPOVIO has the potential to address significant treatment pathway gaps due to a novel treatment mechanism of action Multiple myeloma is one of the most common blood cancers in the UK. 23 April...
Menarini House, Mercury Park, Wycombe Lane, Wooburn Green, High Wycombe, HP10 0HH

0800 085 8678